Yang Jing, Hou Jiali, Li Mengxia
Department of Oncology, Daping Hospital, Army Medical University, Chongqing, 400042, China.
School of Sericulture, Textile and Biomass Science, Southwest University, Chongqing, 400715, China.
J Cancer Res Clin Oncol. 2023 Jan;149(1):357-366. doi: 10.1007/s00432-022-04395-2. Epub 2022 Oct 12.
Apolipoprotein B mRNA-editing catalytic polypeptide (APOBEC) is a family of highly efficient cytidine deaminase enzymes. APOBECs have been proven to deaminate cytidine on single-stranded DNA or RNA. Inducing the deamination of cytosine on the target gene into uracil, which exerts a variety of physiological functions, plays an important role in innate immunity, adaptive immunity, and antiviral. As the research progresses, APOBECs have been confirmed to be highly expressed in a variety of tumors, causing abnormal mutations in host genes, leading to inactivation of tumor suppressor genes or activation of proto-oncogenes, and their role in tumor development and as diagnostic and treatment markers gradually be found.
This article will review the mechanism of APOBECs and their impact on tumor occurrence, development, diagnosis, and treatment, and provide a theoretical basis for future tumor treatment.
载脂蛋白B信使核糖核酸编辑催化多肽（APOBEC）是一类高效的胞嘧啶脱氨酶。已证实APOBEC可使单链DNA或RNA上的胞嘧啶脱氨基。将靶基因上的胞嘧啶脱氨基转变为尿嘧啶，发挥多种生理功能，在固有免疫、适应性免疫及抗病毒方面起重要作用。随着研究进展，已证实APOBEC在多种肿瘤中高表达，导致宿主基因发生异常突变，致使肿瘤抑制基因失活或原癌基因激活，其在肿瘤发生发展及作为诊断和治疗标志物方面的作用逐渐被发现。
本文将综述APOBEC的作用机制及其对肿瘤发生、发展、诊断和治疗的影响，为未来肿瘤治疗提供理论依据。
